We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

40 hedge funds and large institutions have $10.7M invested in NeuBase Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 6 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more capital invested

Capital invested by funds: $3.34M → $10.7M (+$7.39M)

100% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 6

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

5% more funds holding

Funds holding: 38 → 40 (+2)

4% less call options, than puts

Call options by funds: $140K | Put options by funds: $146K

Holders
40
Holders Change
+2
Holders Change %
+5.26%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
12
Reduced
6
Closed
6
Calls
$140K
Puts
$146K
Net Calls
-$6K
Net Calls Change
-$4K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$486K
2
Renaissance Technologies
Renaissance Technologies
New York
+$253K
3
WS
Wedbush Securities
California
+$223K
4
CC
Cannell & Co
New York
+$192K
5
Northern Trust
Northern Trust
Illinois
+$81.1K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$110K
2
UBS Group
UBS Group
Switzerland
-$25.1K
3
VF
Virtu Financial
New York
-$24K
4
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$19.3K
5
Citadel Advisors
Citadel Advisors
Florida
-$18K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.04M +$486K +1,258 +45%
Renaissance Technologies
2
Renaissance Technologies
New York
$1.95M +$253K +654 +33%
WS
3
Wedbush Securities
California
$1.23M +$223K +577 +53%
CC
4
Cannell & Co
New York
$915K +$192K +498 +68%
GBA
5
Garrison Bradford & Associates
New York
$912K -$6.95K -18 -1%
BlackRock
6
BlackRock
New York
$779K +$772 +2 +0.2%
Northern Trust
7
Northern Trust
Illinois
$258K +$81.1K +210 +152%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$257K -$12.4K -32 -8%
UCFA
9
United Capital Financial Advisors
Texas
$161K – – –
California Public Employees Retirement System
10
California Public Employees Retirement System
California
$147K – – –
LCM
11
Leisure Capital Management
California
$122K +$1.54K +4 +3%
Creative Planning
12
Creative Planning
Kansas
$115K +$772 +2 +1%
Neuberger Berman Group
13
Neuberger Berman Group
New York
$86K – – –
CCB
14
Cutter & Co Brokerage
Missouri
$74K +$1.16K +3 +3%
FPF
15
FNY Partners Fund
New York
$74K +$38.6K +100 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$64K – – –
MIG
17
Mariner Investment Group
New York
$56K +$29K +75 New
HighTower Advisors
18
HighTower Advisors
Illinois
$52K – – –
Group One Trading
19
Group One Trading
Illinois
$48K +$25.1K +65 New
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$47K +$24.3K +63 New
FNBT
21
FineMark National Bank & Trust
Florida
$42K – – –
JP Morgan Chase
22
JP Morgan Chase
New York
$41K +$21.2K +55 New
Deutsche Bank
23
Deutsche Bank
Germany
$37K – – –
SM
24
Salzhauer Michael
$35K -$16.2K -42 -47%
SIP
25
Stoneridge Investment Partners
Pennsylvania
$26K -$772 -2 -5%
1
2

NBSE Hedge Fund Activity: Q4 2017 in Review

40 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2017, worth a combined $10.7M — up 222% from $3.34M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new NBSE positions and 6 closed out — a net gain of 2 holders — while 12 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $486K. The largest seller was Sabby Management, exiting entirely with an estimated $110K sold.

  • 40 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2017, up from 38 in Q3 2017.
  • Funds reported $10.7M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2017, up 222% quarter-over-quarter.
  • 8 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2017 and 6 closed out, a net change of +2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2017 was Vanguard Group, an estimated $486K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2017 was Sabby Management, an estimated $110K sold.

Based on aggregated 13F filings for Q4 2017.